DR. SHYAM SUNDAR DAS MOHAPATRA

Abstract

Retrospective analysis of intraocular pressure (IOP) changes was carried out in 50 consecutive patients who had received intravitreal dexamethasone (Ozurdex, 0.7mg) implant in a tertiary eye care hospital. Total of 50 patients (total 65 eyes), mean age of 62.08 years, were included in this study. Most common indication for intravitreal dexamethasone (Ozurdex, 0.7mg) implant was Diabetic Macular Edema (DME). Out of the 65 eyes, IOP rise (>21 mmHg) occurred in 29.23% eyes, of which 31.57% eyes had IOP spikes >30 mmHg. In IOP-rise group, 78.94% and 21.05% had maximum IOP rise in 4 week and 12 week follow-up respectively, 63.15% controlled with antiglaucoma medication, of which 66.66% required 2 medications. Intravitreal dexamethasone (Ozurdex, 0.7mg) can cause rise in IOP. Maximum IOP rise was noted within first 4 weeks of intravitreal dexamethasone (Ozurdex, 0.7mg) implantation. Close follow-up, IOP monitoring and timely intervention is necessary for successful management.